Anti-Human GD2 (Dinutuximab)

Anti-Human GD2 (Dinutuximab)

Product No.: G160

- -
- -
Product No.G160
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
human ganglioside GD2, disialoganglioside
Human IgG1κ

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Expression Host
HEK-293 Cells
FC Effector Activity
Recommended Isotype Controls
Humanized antibody derived from mouse clone ch14.18
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
≥95% by SDS Page
≥95% monomer by analytical SEC
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
2-8°C Wet Ice
Additional Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Dinutuximab activity is directed against human disialoganglioside (GD2).
Antigen Distribution
GD2 is a cell surface glycolipid present in low concentrations on skin, neural or peripheral nerve cell surfaces. GD2 is overexpressed on neuroblastoma cells, most melanoma, and some other tumors.
Neuroblastoma is an extracranial childhood cancer that accounts for 12% of cancer deaths in children1. Neuroblastomas highly express the antigen GD2, a glycolipid which assists in the attachment of tumor cells to the extracellular matrix2.

Dinutuximab is a mouse-human chimeric monoclonal antibody to disialoganglioside (GD2) 3. Engagement of dinutuximab with GD2 triggers antibody dependent cell cytotoxicity and complement dependent cytotoxicity, the effectiveness of which is increased by coadministration with granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-12), and 13-cis retinoic acid (isotretinoin).

Dinutuximab, also known as ch14.18, was developed as an IgG1 human/mouse chimeric switch variant of murine monoclonal antibody 14.18 4. Dinutuximab is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and κ light-chain. Dinutuximab is produced in the murine myeloma cell line SP2/O and has an approximate molecular weight of 150 kDa 5. Studies have also tested the efficacy of dinutuximab grown in Chinese hamster ovary (CHO) cells (ch14.18/CHO)6,7.

Antigen Details

Research Area

References & Citations

1. Aust Prescr. 43(6):212-213. 2020.
2. Hoy SM. Target Oncol. 11(2):247-253. 2016.
3. Dhillon S. Drugs. 75(8):923-927. 2015.
4. Mueller BM, Romerdahl CA, Gillies SD, et al. J Immunol. 144(4):1382–1386. 1990.
5. https://
6. Ladenstein R, Weixler S, Baykan B, et al. MAbs. 5(5):801-809. 2013.
7. Ladenstein R, Pötschger U, Valteau-Couanet D, et al. Lancet Oncol. 19(12):1617-1629. 2018.
8. Barker E, Mueller BM, Handgretinger R, et al. Cancer Res. 51(1):144–149. 1991.
9. Yu AL, Gilman AL, Ozkaynak MF, et al. N Engl J Med. 363(14):1324–1334. 2010.
Indirect Elisa Protocol
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.